PT - JOURNAL ARTICLE AU - AT. Matelski AU - N. Siddique AU - P. Mead AU - T. Raimondi AU - L. Jorgenson AU - O. Calderon AU - K. Harman AU - JJ. Farrell TI - Microscopic Review of Nasopharyngeal Swabs as a Means of Benchside Quality Assurance AID - 10.1101/2020.04.06.20050088 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.06.20050088 4099 - http://medrxiv.org/content/early/2020/04/07/2020.04.06.20050088.short 4100 - http://medrxiv.org/content/early/2020/04/07/2020.04.06.20050088.full AB - Nasopharygneal swabs (NPS) are the collection modality recommended by the Centers for Disease Control and Prevention (CDC) for reverse-transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV2. NPS gather both extracellular material and human respiratory epithelial cells and, when used with RT-PCR, have reliable sensitivity for detection of viral infection. However, at our institution, we identified a 1.7% re-order rate within 7-days for NPS for respiratory pathogen RT-PCR, which we hypothesize may be due to low confidence in adequate sample collection. We sought to identify an inexpensive and accessible strategy for benchside quality assurance of NPS adequacy by observing microscopic content of viral transport media. For 801 NPS samples collected in November 2019, we air-dried and safranin-stained aliquots of viral transport media on glass slides. We then counted morphologically distinct ciliated columnar epithelial cells (CCEs). 19% of samples negative by RT-PCR for respiratory pathogens had no CCEs, while just 6% of positive samples exhibited the same. Pearson’s Chi-squared test was used to compare presence of CCEs between samples that were positive and negative for respiratory pathogens by RT-PCR (p=3.3×10-38). The negative predictive value (NPV) of finding no identifiable CCEs on microscopy was 85%. We posit that samples without identifiable CCEs may have been inadequately collected. The basic, benchside protocol using inexpensive laboratory reagents that we describe here could help improve accuracy and accessibility of NPS and RT-PCR testing for SARS-CoV2 and other respiratory pathogens while conserving limited resources in the face of a pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo authors received payment from any third party for any aspect of the submitted work. This work was undertaken in the OSF System Laboratory as part of usual quality improvement and received no external grants nor funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon publication in a peer-reviewed journal.